Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica

Ireland - English - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 2 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - tablets - dexamethasone 0.5 mg - dexamethasone - dexamethasone - indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.

Ireland - English - HPRA (Health Products Regulatory Authority)

taw pharma (ireland) ltd - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dexamethasone sodium phosphate, quantity: 4.4 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection - excipient ingredients: sodium citrate; creatinine; water for injections - replacement therapy:,adrenocortical insufficiency - dexamethasone has predominantly glucocorticoid activity and, therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in the following: ? acute adrenocortical insufficiency - addison's disease; bilateral adrenalectomy ? relative adrenocortical insufficiency prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should, therefore be reinstituted to help cope with stress such as that a

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dexamethasone sodium phosphate, quantity: 8.8 mg (equivalent: dexamethasone phosphate, qty 8 mg) - injection - excipient ingredients: water for injections; sodium citrate; creatinine - replacement therapy:,adrenocortical insufficiency - dexamethasone has predominantly glucocorticoid activity and, therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in the following: ? acute adrenocortical insufficiency - addison's disease; bilateral adrenalectomy ? relative adrenocortical insufficiency prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should, therefore be reinstituted to help cope with stress such as that a

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexamethasone 0.5mg - tablet - 0.5 mg - active: dexamethasone 0.5mg excipient: lactose monohydrate magnesium stearate povidone wheat starch - dexamethasone is indicated for replacement therapy in secondary adrenal insufficiency arising from insufficient corticotrophin secretion. it is not indicated for primary adrenal insufficiency states, such as addisons disease or after adrenalectomy. in such cases hydrocortisone and fludrocortisone in combination is more appropriate. dexamethasone is also indicated for allergic disorders such as bronchial asthma and allergic skin reactions, blood disorders such as leukaemia, thrombocytopoenia and haemolytic anaemias, selected collagen and rheumatic disorders (only rarely in rheumatoid arthritis), gastrointestinal disorders such as inflammatory bowel disease, connective tissue disorders such as arteritis, systemic lupus erythematosus (but not scleroderma), some skin diseases such as pemphigus, oedema, some eye disorders, certain neoplastic disorders such as cerebral neoplasm, secondary hypercalcaemia, and acute leukaemia in children. it may also be used to prevent neonatal respiratory distress syndrome and in the diagnosis of cushing's syndrome. dexamethasone is indicated in the treatment of coronavirus disease 2019 (covid-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexamethasone 4mg - tablet - 4 mg - active: dexamethasone 4mg excipient: lactose monohydrate magnesium stearate maize starch povidone - dexamethasone is indicated for replacement therapy in secondary adrenal insufficiency arising from insufficient corticotrophin secretion. it is not indicated for primary adrenal insufficiency states, such as addisons disease or after adrenalectomy. in such cases hydrocortisone and fludrocortisone in combination is more appropriate. dexamethasone is also indicated for allergic disorders such as bronchial asthma and allergic skin reactions, blood disorders such as leukaemia, thrombocytopoenia and haemolytic anaemias, selected collagen and rheumatic disorders (only rarely in rheumatoid arthritis), gastrointestinal disorders such as inflammatory bowel disease, connective tissue disorders such as arteritis, systemic lupus erythematosus (but not scleroderma), some skin diseases such as pemphigus, oedema, some eye disorders, certain neoplastic disorders such as cerebral neoplasm, secondary hypercalcaemia, and acute leukaemia in children. it may also be used to prevent neonatal respiratory distress syndrome and in the diagnosis of cushing's syndrome. dexamethasone is indicated in the treatment of coronavirus disease 2019 (covid-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.